Interpace Biosciences Inc (STU:PF42)
€ 2.32 -0.14 (-5.69%) Market Cap: 11.03 Mil Enterprise Value: 15.96 Mil PE Ratio: 2.40 PB Ratio: 0 GF Score: 39/100

Q4 2018 Interpace Diagnostics Group Inc Earnings Call Transcript

Mar 19, 2019 / 08:30PM GMT
Release Date Price: €8.24 (+4.17%)
Operator

Greetings, and welcome to the Interpace Diagnostics Group Fourth Quarter and Full Year 2018 Financial Results, Business Progress and Recent Announcements Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I'd like to turn the conference over to your host, Jack Stover, CEO. Thank you, you may begin.

Jack E. Stover
Interpace Diagnostics Group, Inc. - CEO, President and Director

Thank you, Matt, and good afternoon, and thank you for joining us today for a review of our fourth quarter and fiscal year ended December 31, 2018 as well as activities to date.

With me today is Jim Early, our Chief Financial Officer. After my overview, Jim will review our financial performance with you in more detail. Following that, we will open the call for your questions.

Let me remind you of our mission here at Interpace as I do on all calls. We are a fully integrated commercial and bioinformatics company that provides molecular and related first-line diagnostic tests and pathology services by leveraging the latest

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot